Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert F Lobuglio

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapsePierre L Triozzi, Wayne Aldrich, Karen O Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanomaPierre L Triozzi, Karen O Allen, Ronda R Carlisle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2002
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Plos One|September 14, 2011
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancerSomaira Nowsheen, James A Bonner, Albert F Lobuglio, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanomaAndres Forero, Jatin Shah, Ronda Carlisle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11Patsy G Oliver, Albert F LoBuglio, Kurt R Zinn, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Breast Cancer Research and Treatment|September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityAngelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer modelDonald J Buchsbaum, Tong Zhou, William E Grizzle, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 8, 2005
Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapsePierre L Triozzi, Wayne Aldrich, Karen O Allen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanomaPierre L Triozzi, Karen O Allen, Ronda R Carlisle, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 7, 2002
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapySui Shen, Ruby F Meredith, Jun Duan, et al.
Plos One|September 14, 2011
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancerSomaira Nowsheen, James A Bonner, Albert F Lobuglio, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 30, 2007
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanomaAndres Forero, Jatin Shah, Ronda Carlisle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11Patsy G Oliver, Albert F LoBuglio, Kurt R Zinn, et al.
Cancer Biotherapy & Radiopharmaceuticals|November 25, 2003
A novel monoclonal antibody design for radioimmunotherapyAndres Forero, Ruby F Meredith, M B Khazaeli, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 6, 2005
Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignanciesSui Shen, Andres Forero, Albert F LoBuglio, et al.
Breast Cancer Research and Treatment|September 15, 2011
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityAngelina I Londoño-Joshi, Patsy G Oliver, Yufeng Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer modelDonald J Buchsbaum, Tong Zhou, William E Grizzle, et al.
Pageof 6